Key result
Congenital heart disease survivors face ~71% higher cancer risk compared to the general population.
Why the study?
Improved survival in congenital heart disease has shifted attention toward acquired conditions like cancer, yet no broad CHD-specific cancer screening guideline currently exists.
This narrative review synthesizes evidence showing an elevated lifetime cancer risk in congenital heart disease survivors and proposes a pragmatic three-tier risk-stratified surveillance algorithm to balance early detection against unnecessary testing.
Answers are grounded in this paper and cite their sources.
May warrant considering enhanced cancer surveillance in congenital heart disease survivors; extends observational data but leaves optimal strategies open.
Improved survival in congenital heart disease (CHD) has shifted attention toward acquired conditions that emerge across the life course, including cancer. This structured narrative review updates epidemiologic, mechanistic, and surveillance evidence through 2025 and proposes a practical framework for clinical risk assessment. A 2025 systematic review and meta-analysis of six observational studies involving 276,124 participants reported a pooled cancer hazard ratio of 1.71 (95% confidence interval: 1.28–2.28); the estimate remained elevated after adjustment for chromosomal abnormalities (1.54, 95% confidence interval: 1.24–1.91), although between-study heterogeneity was substantial. Large registry studies show that risk is not uniform: it is influenced by age, CHD complexity, early procedures, genetic syndromes, transplantation, and cumulative medical exposure. Potential mechanisms include ionizing radiation, chronic hypoxemia with hypoxia-inducible factor signaling and oxidative stress, Fontan-associated hepatic congestion and fibrosis, altered immune surveillance after thymectomy, shared developmental genetics, and modifiable lifestyle factors. No broad CHD-specific cancer screening guideline currently exists. This review therefore proposes a three-tier surveillance algorithm that preserves standard population screening for most survivors, adds structured annual risk review for those with cumulative exposures or complex physiology, and applies condition-specific surveillance for clearly defined high-risk groups, particularly Fontan-associated liver disease and genetic syndromes. The proposed framework is intended for prospective validation rather than immediate replacement of established national screening guidelines.
No takes yet. Share an insight, caveat, or question.
Josephine Ushang Adie (2026) conducted a review in Congenital heart disease (n=276,124). Congenital heart disease vs. General population / matched controls without congenital heart disease was evaluated on Cancer incidence (HR 1.71, 95% CI 1.28–2.28). Congenital heart disease survivors have an increased risk of developing cancer compared to the general population.
Synapse has enriched 10 related papers. Consider them for comparative context: